PEOPLE - CR Bard makes appointment:
This article was originally published in Clinica
Vascular, urology and oncology technology developer CR Bard (Murray Hill, New Jersey) has elected Gail Naughton to its board of directors. Ms Naughton serves for San Diego State University, and prior to this, served for over 15 years at Advanced Tissue Sciences, where she was the company's co-founder and co-inventor of its core technology. She also held executive roles such as president, COO, chief scientific officer and principal scientist.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.